Seattle Genetics grabs tumor drug of Immunomedics in $2B deal


February 10, 2017

Seat­tle Ge­net­ics has become the new flag car­rier for the solid tumor drug IMMU-132 of   Im­munomedics. In order to claim global rights on the drug, Seat­tle Ge­net­ics is pay­ing $300 mil­lion, and also com­mit­ting up to $1.7 bil­lion more in mile­stones. The biotech will now take the lead on a Phase III study for metasta­tic triple neg­a­tive breast can­cer. And once the BLA is filed, it’s ob­lig­ated to pay over the first of its mile­stone money as Seat­tle Ge­net­ics looks to vault to an ap­proval as early as late 2017.

NJ-based Im­munomedics CEO Cyn­thia L. Sul­li­van said: “In just over three years, we have brought IMMU-132 through clin­i­cal de­vel­op­ments in mul­ti­ple in­di­ca­tions, and have ad­vanced the TNBC in­di­ca­tion to a po­ten­tial ac­cel­er­ated ap­proval and launch by late 2017 or early 2018, which could make IMMU-132 avail­able to pa­tients deal­ing with a highly ma­lig­nant form of breast can­cer,”

IMMU-132 (sac­i­tuzumab govite­can) fits squarely in the com­fort zone Seat­tle Ge­net­ics. It is an armed an­ti­body that con­tains SN-38, the ac­tive metabo­lite of irinote­can, de­signed for pre­cise de­liv­ery to avoid off-tar­get tox­i­c­ity.

The deal — with a $250 mil­lion in an up­front and an ad­di­tional $50 mil­lion for ad­di­tional ex-US rights — falls just days after Sul­li­van and her crew declared the lat­est up­date on the drug and its plans to seek an ac­cel­er­ated ap­proval.


Seattle Genetics grabs tumor drug of Immunomedics in $2B deal last edit: 2017-02-15T16:53:15+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar